Many investigators have shown increased efficacy in cell and animal tumor models by conjugating drugs to HA or anti-CD44 antibodies and incorporating drugs or siRNAs into vehicles decorated with HA or antibodies [10,11]. The gene discussed is CD44; the disease is neoplasm.